Pharma IQ Members


Biosimilars, also referred to as Follow-on Biologics, is a term used to describe officially-approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Biosimilars are also referred to as subsequent entry biologics (SEBs) in Canada. Similar biological medicinal products are often called biosimilars.

Global Biosimilars Outlook 2011

“I think it’s fair to say that we expect in the 2015 to 2020 period, biosimilars will see a high rate of growth and share of the market.” Murray Aitken, Executive Director, IMS Institute for Healthcare Informatics. Biosimilars hold the promise of...

Contributor: Pharma IQ
Thu, 08/25/2011
Biosimilar Capabilities and Market Potential in Asia

Epogen, Neupogen and Enbrel are three biologics which have already seen their patents expire, and Herceptin and Avastin are to be added to this list in the not too distant future. By 2015 the global market for biosimilars is expected to reach $4....

Contributor: Pharma IQ
Wed, 06/29/2011
Pharma IQ

It was only matter of time before the United States Food and Drug Administration (FDA) put in place guidance for the marketing of biosimiliars – and it would seem that time is almost upon us. Global spending on biosimilars is expected to reach $2...

Contributor: Pharma IQ
Tue, 05/17/2011